01 / Company statusDisclosed
Planckchron is founder-led, early-stage, and pre-revenue.
Canonical company facts and public company-state language.
Evidence registry / Public diligence
Evidence before promotion.
Planckchron distinguishes disclosed company facts, strategy, research targets, prototype observations, and independently reviewable results. No technical metric is represented as validated without a dated method, test conditions, limitations, and supporting evidence.
FactsCorporate and operating statements supported by records
StrategyManagement choices and sequencing—not achieved results
TargetsFuture objectives clearly separated from present capability
Validated resultsPublished only with method, limits, date, and evidence
Public claims register
What is known—and what is not yet proven.
This register is deliberately conservative. A missing benchmark is preferable to an unsupported benchmark because credibility compounds only when public claims survive diligence.
02 / Portfolio maturityDisclosed
Each program is labeled prototype or development until a paid customer workflow exists.
Canonical investment-readiness registry used across public investor and proof pages.
03 / HERA NexusStrategy
HERA is the near-term commercial wedge for the portfolio.
90-day scorecard, 18-month de-risking plan, and design-partner validation sequence.
04 / HERA reference workflowStrategy
Technical Evidence Review & Approval is the current v1 validation target.
Public HERA workflow specification and management scorecard; not represented as a customer deployment.
05 / Technical benchmarksNot yet validated
No public qubit, gate-fidelity, AI-accuracy, screening-throughput, drug-candidate, HERA cycle-time, or ROI result is represented as validated.
Metrics remain unpublished until a dated method, conditions, limitations, and reproducible result are available.
06 / Commercial tractionDisclosed
A design-partner engagement is in place. No revenue, paid pilot, or signed customer contract is represented at this time.
Commercial claims will be updated only after documentary evidence exists.
Canonical maturity register
One portfolio. One source of truth.
Every public investor and evidence page uses the same maturity labels, sequencing, objectives, and next evidence gates.
01 / Commercial wedgeDevelopment
HERA Nexus
Artificial intelligence. Validate Technical Evidence Review & Approval as one human-supervised workflow with a qualified design partner and measurable operating outcomes.
Next evidence gate: Controlled external evaluation, security artifacts, published evidence records, and a documented path to a paid pilot.
Review program
02 / Long-horizon R&DDevelopment
Athena
Clinical decision support. Build evidence-linked chart synthesis and review summaries that keep a named clinician accountable for every output, ahead of any clinical evaluation.
Next evidence gate: Retrospective de-identified dataset, a documented review protocol, clinician-in-the-loop error analysis, and an independent methodology review.
Review program
03 / Adjacent validationDevelopment
EchoNet
Resilient communications. Demonstrate bounded coordination and graceful degradation in a controlled network environment.
Next evidence gate: Documented test method, network conditions, repeatable results, and failure analysis.
Review program
04 / Adjacent validationDevelopment
Helios Autonomy
Autonomous systems. Test accountable perception, planning, escalation, and human intervention boundaries in simulation.
Next evidence gate: Scenario suite, intervention criteria, recorded decisions, and independent technical review.
Review program
05 / Long-horizon R&DDevelopment
Aetherion Core
Emerging compute. Define and test the most consequential assumptions in the post-silicon and hybrid compute architecture.
Next evidence gate: Published architecture note, simulation method, reproducible model, and clearly labeled limitations.
Review program
06 / Long-horizon R&DDevelopment
BioForge + GenovaX
Biotechnology. Develop evidence-aware research workflows and identify one bounded biotechnology use case for external review.
Next evidence gate: Defined research question, responsible-review process, reproducible workflow, and qualified domain partner.
Review program
07 / Long-horizon R&DDevelopment
PX-Phantom
Aerospace systems. Convert the aerospace thesis into a simulation-led research program with explicit engineering constraints.
Next evidence gate: Requirements baseline, simulation assumptions, engineering review, and dated test plan.
Review program
Validation standard
A result earns publication.
Planckchron's public standard is designed to prevent marketing language from outrunning technical reality.
Define the claim
State exactly what is being tested, what is excluded, and why the result matters.
Publish the method
Record the configuration, dataset, operating conditions, responsible reviewer, and known limitations.
Separate target from result
A projection, simulation, prototype observation, and validated benchmark must never share the same label.
Invite challenge
Material claims should be reproducible, reviewable, and corrected when stronger evidence becomes available.
18-month de-risking plan
Progress is measured by decisions earned.
The near-term plan prioritizes HERA Nexus while preserving all seven programs behind explicit evidence gates.
0–3 months
Freeze the HERA v1 problem definition, customer profile, Technical Evidence Review & Approval workflow, technical architecture, security boundary, and measurement plan.
Proceed only with a named accountable workflow and an external design-partner signal.4–6 months
Deliver a bounded HERA prototype with evidence capture, Decision Packets, human approval, intervention controls, role permissions, and audit history.
Proceed only if the prototype reduces a measurable workflow failure or operating burden in controlled evaluation.7–12 months
Run controlled design-partner evaluations and publish dated evidence records for the primary workflow when disclosure is permitted.
Proceed only with retained use, credible user pull, and a defined path to a paid pilot.13–18 months
Convert validated use into paid pilot activity while advancing one EchoNet or Helios adjacent validation program only if HERA evidence supports expansion.
Scale headcount and capital only when technical evidence, governance, and economics support expansion.Qualified diligence
Review the evidence behind the company—not a promotional proxy.
Qualified investors and aligned design partners may request the operating plan, capitalization materials, technical assumptions, milestone budget, and non-public evidence subject to eligibility and confidentiality.
